Pozen (POZN) +13.3% premarket after the biotech company announces positive top-line results from...

|By:, SA News Editor

Pozen (POZN) +13.3% premarket after the biotech company announces positive top-line results from two pivotal Phase 3 clinical trials of PA32540, its new proton pump inhibitor with aspirin for cardiovascular disease patients who are also at risk of gastric ulcers.